Takizawa H, DelliPizzi A M, Nasjletti A
Department of Pharmacology, New York Medical College, Valhalla 10595, USA.
Hypertension. 1998 Mar;31(3):866-71. doi: 10.1161/01.hyp.31.3.866.
Lipoxygenase inhibitors reduce blood pressure in hypertensive rats. The vasodepressor effect of lipoxygenase inhibitors may be related to increased production of prostaglandin (PG) I2 since lipoxygenase-derived fatty acid hydroperoxides inhibit PGI2 synthase. This hypothesis was examined in rats made hypertensive by infusion of angiotensin II (200 ng/min i.p.) for 12 to 14 days. In hypertensive but not in normotensive rats, the lipoxygenase inhibitor baicalein (60 mg/kg s.c.) increased (P<.05) the conversion of exogenous PGH2 to PGI2 by aortic segments, the release of 6-keto-PGF1alpha by aortic rings, the concentration of 6-keto-PGF1alpha in blood, and the renal excretion of 6-keto-PGF1alpha. Treatment with baicalein did not affect the blood pressure of normotensive rats but decreased the blood pressure of hypertensive rats from 177+/-8 to 133+/-9 mm Hg after 120 minutes (P<.05). Also, the lipoxygenase inhibitor cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate (8 mg/kg s.c.) was without effect on the blood pressure of normotensive rats but decreased the blood pressure of hypertensive rats from 182+/-4 to 139+/-8 mm Hg (P<.05). However, the blood pressure of hypertensive rats pretreated with indomethacin (5 mg/kg i.v.) was affected by neither baicalein nor cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate. Moreover, in hypertensive rats in which baicalein had decreased blood pressure to 148+/-6 mm Hg, the administration of rabbit serum containing antibodies against 5,6-dihydro-PGI2 (0.3 mL i.v.) partially reversed the response to baicalein, increasing blood pressure to 179+/-7 mm Hg within 20 minutes (P<.05). The antibodies also were shown to block the vasodepressor effect of PGI2 but not of PGE2. Collectively, these data suggest contribution of PGI2 to the acute antihypertensive effect of baicalein in rats with angiotensin II-induced hypertension.
脂氧合酶抑制剂可降低高血压大鼠的血压。脂氧合酶抑制剂的血管降压作用可能与前列腺素(PG)I2生成增加有关,因为脂氧合酶衍生的脂肪酸氢过氧化物会抑制PGI2合酶。在通过腹腔注射血管紧张素II(200 ng/分钟)12至14天诱导高血压的大鼠中检验了这一假说。在高血压大鼠而非正常血压大鼠中,脂氧合酶抑制剂黄芩苷(60 mg/kg皮下注射)可增加(P<0.05)主动脉段将外源性PGH2转化为PGI2的能力、主动脉环释放6-酮-PGF1α的量、血液中6-酮-PGF1α的浓度以及6-酮-PGF1α的肾排泄量。黄芩苷处理对正常血压大鼠的血压无影响,但120分钟后可使高血压大鼠的血压从177±8降至133±9 mmHg(P<0.05)。此外,脂氧合酶抑制剂肉桂基-3,4-二羟基-α-氰基肉桂酸酯(8 mg/kg皮下注射)对正常血压大鼠的血压无影响,但可使高血压大鼠的血压从182±4降至139±8 mmHg(P<0.05)。然而,用吲哚美辛(5 mg/kg静脉注射)预处理的高血压大鼠的血压,既不受黄芩苷也不受肉桂基-3,4-二羟基-α-氰基肉桂酸酯的影响。此外,在黄芩苷已将血压降至148±6 mmHg的高血压大鼠中,静脉注射含有抗5,6-二氢-PGI2抗体的兔血清(0.3 mL)可部分逆转对黄芩苷的反应,使血压在20分钟内升至179±7 mmHg(P<0.05)。这些抗体还显示可阻断PGI2的血管降压作用,但不阻断PGE2的作用。总体而言,这些数据表明PGI2对黄芩苷在血管紧张素II诱导的高血压大鼠中的急性降压作用有贡献。